PDCD1 and neoplasm: The recent development of immune checkpoints, represented by programmed cell death protein 1 (PD‐1)/PD‐ligand 1 (PD‐L1) and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), has revived interest in tumour immunotherapy.1